Overview Cetuximab and Lenalidomide in Head and Neck Status: Completed Trial end date: 2012-08-01 Target enrollment: Participant gender: Summary The purpose of this study is to study specific FcRIIIa polymorphisms and their correlation with clinical outcome in subjects treated with cetuximab and lenalidomide. Phase: Phase 2 Details Lead Sponsor: University of ChicagoCollaborator: Celgene CorporationTreatments: CetuximabLenalidomideThalidomide